Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Pyxis Oncology Inc (NASDAQ: PYXS) closed at $4.20 down -2.10% from its previous closing price of $4.29. In other words, the price has decreased by -$2.10 from its previous closing price. On the day, 0.54 million shares were traded. PYXS stock price reached its highest trading level at $4.33 during the session, while it also had its lowest trading level at $4.01.
Ratios:
For a deeper understanding of Pyxis Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.84 and its Current Ratio is at 12.19. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
On February 09, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $8.
On January 23, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $12.Leerink Partners initiated its Outperform rating on January 23, 2024, with a $12 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 28 ’23 when Connealy Pamela Ann bought 8,000 shares for $1.87 per share. The transaction valued at 14,960 led to the insider holds 818,532 shares of the business.
Connealy Pamela Ann bought 6,426 shares of PYXS for $11,868 on Sep 27 ’23. The CFO and COO now owns 810,532 shares after completing the transaction at $1.85 per share. On Sep 27 ’23, another insider, Wadhane Jitendra, who serves as the Chief Accounting Officer of the company, bought 2,500 shares for $1.87 each. As a result, the insider paid 4,675 and bolstered with 226,937 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 252579584 and an Enterprise Value of 146193168. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.31 while its Price-to-Book (P/B) ratio in mrq is 1.34.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $6.85, while it has fallen to a 52-week low of $1.35. The 50-Day Moving Average of the stock is -13.90%, while the 200-Day Moving Average is calculated to be 37.80%.
Shares Statistics:
For the past three months, PYXS has traded an average of 733.05K shares per day and 462220 over the past ten days. A total of 58.88M shares are outstanding, with a floating share count of 46.86M. Insiders hold about 20.40% of the company’s shares, while institutions hold 33.80% stake in the company. Shares short for PYXS as of 1714435200 were 1849743 with a Short Ratio of 2.52, compared to 1711584000 on 2702190. Therefore, it implies a Short% of Shares Outstanding of 1849743 and a Short% of Float of 3.94.
